Patients' preferences for chemotherapy in non-small-cell lung cancer: A systematic review

Lung Cancer

Volumn 69, Issue 2, 2010, Pages 141-147

  Blinman, Prunella ^a   Alam, Mahmood ^b   Duric, Vlatka ^a   McLachlan, Sue Anne ^c,d   Stockler, Martin R ^a,e  

^a UNIVERSITY OF SYDNEY   (Australia)

^b LIVERPOOL HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Chemotherapy; Decision making; Non small cell lung cancer; Patients; Preferences; Trade offs

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ATTITUDE TO HEALTH; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; PATIENT ATTITUDE; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW;

AGE FACTORS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; DEMOGRAPHY; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; NORTH AMERICA; PATIENT PREFERENCE; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 77954142193     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.05.001     Document Type: Review

References (35)

1. Coleman M.P., Quaresma M., Berrino F., Lutz J.-M., De Angelis R., Capocaccia R., et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008, 9(8):730-756.
2. Goldstraw P., Crowley J., Chansky K., Giroux D.J., Groome P.A., Rami-Porta R., et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007, 2(8):706-714. [see comment][erratum appears in J Thorac Oncol 2007 Oct;2(10):985].
3. Pignon J.-P., Tribodet H., Scagliotti G.V., Douillard J.-Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008, 26(21):3552-3559.
4. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26(28):4617-4625. NSCLC Meta-Analyses Collaborative Group.
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995, 311(7010):899-909. Non-small Cell Lung Cancer Collaborative Group, [see comment].
6. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase iii study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21(16):3016-3024.
7. Belani C.P., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 2006, 53(2):231-239.
8. Jacob S., Hovey E., Ng W., Vinod S., Delaney G.P., Barton M.B. Estimation of an optimal chemotherapy utilisation rate for lung cancer: an evidence-based benchmark for cancer care. Lung Cancer 2010, 10.1016/j.lungcan.2009.11.017.
9. Patel N., Adatia R., Mellemgaard A., Jack R., Moller H. Variation in the use of chemotherapy in lung cancer. Br J Cancer 2007, 96(6):886-890.
10. Vinod S.K., O'Connell D.L., Simonella L., Delaney G.P., Boyer M., Peters M., et al. Gaps in optimal care for lung cancer. J Thorac Oncol 2008, 3(8):871-879.
11. American College of Surgeons. National cancer database benchmark reports. 2009 [cited 2010 16.2]. Available from: http://cromwell.facs.org/BMarks/BMPub/Ver9/DxRx/BMPub_DxRx9.cfm.
12. Jennens R.R., de Boer R., Irving L., Ball D.L., Rosenthal M.A. Differences of opinion: a survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 2004, 126(6):1985-1993.
13. Kassam F., Shepherd F.A., Johnston M., Visbal A., Feld R., Darling G., et al. Referral patterns for adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. J Thorac Oncol 2007, 2(1):39-43.
14. Earle C.C., Neumann P.J., Gelber R.D., Weinstein M.C., Weeks J.C. Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol 2002, 20(7):1786-1792.
15. Schroen A.T., Detterbeck F.C., Crawford R., Rivera M.P., Socinski M.A. Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 2000, 118(1):129-137.
16. Younis T., Al-Fayea T., Virik K., Morzycki W., Saint-Jacques N. Adjuvant chemotherapy uptake in non-small cell lung cancer. J Thorac Oncol 2008, 3(11):1272-1278.
17. Simes R.J., Coates A.S. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?. J Natl Cancer Inst Monogr 2001, 30:146-152.
18. Duric V., Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile?. Lancet Oncol 2001, 2(11):691-697.
19. Blinman P.L., Duric V.M., Nowak A.K., Beale P., Clarke S.J., Briscoe K., et al. Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile?. Eur J Cancer 2010, 10.1016/j.ejca.2009.12.032.
20. Brundage M.D., Davidson J.R., Mackillop W.J. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997, 15(1):330-340.
21. Silvestri G., Pritchard R., Welch H.G. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998, 317(7161):771-775.
22. Brundage M.D., Feldman-Stewart D., Cosby R., Gregg R., Dixon P., Youssef Y., et al. Cancer patients' attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns 2001, 45(2):149-157.
23. Hirose T., Horichi N., Ohmori T., Kusumoto S., Sugiyama T., Shirai T., et al. Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 2005, 44(2):107-113.
24. Hirose T., Yamaoka T., Ohnishi T., Sugiyama T., Kusumoto S., Shirai T., et al. Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psychooncology 2009, 18(5):483-489.
25. Nafees B., Stafford M., Gavriel S., Bhalla S., Watkins J. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008, 6:p84.
26. Chu D.-T., Kim S.-W., Kuo H.-P., Ozacar R., Salajka F., Krishnamurthy S., et al. Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer. Lung Cancer 2007, 56(3):433-443.
27. Brundage M.D., Feldman-Stewart D., Cosby R., Gregg R., Dixon P., Youssef Y., et al. Phase I study of a decision aid for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2001, 19(5):1326-1335.
28. Brundage M.D., Davidson J.R., Mackillop W.J., Feldman-Stewart D., Groome P. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making 1998, 18(3):256-267.
29. Curran W.J., Scott C., Langer C., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential v. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 2003, 22:621. [abstr 2499].
30. Jansen S.J.T., Otten W., Stiggelbout A.M. Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 2004, 22(15):3181-3190.
31. Dubey S., Brown R.L., Esmond S.L., Bowers B.J., Healy J.M., Schiller J.H., et al. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol 2005, 3(2):149-154.
32. Nilchaikovit T., Hill J.M., Holland J.C. The effects of culture on illness behavior and medical care: Asian and American differences. Gen Hosp Psychiatry 1993, 15(1):41-50.
33. Ruhnke G.W., Wilson S.R., Akamatsu T., Kinoue T., Takashima Y., Goldstein M.K., et al. Ethical decision making and patient autonomy: a comparison of physicians and patients in Japan and the United States. Chest 2000, 118(4):1172-1182. [see comment].
34. Gotay C.C., Shimizu H., Muraoka M., Ishihara Y., Tsuboi K., Ogawa H., et al. Cancer-related attitudes: a comparative study in Japan and the US. Psychooncology 2004, 13(9):665-672.
35. Stockler M.R., Tattersall M.H.N., Boyer M.J., Clarke S.J., Beale P.J., Simes R.J., et al. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2005, 94(2):208-212.